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Cost analysis was accepted at the Barcelona conference as a
special topic--this is the first time an international meeting has
included the subject. The two major areas where cost analysis is
urgently required in a medical laboratory which has an
increasing lack of funds are in the discussion of strategies for
selecting tests (which test, for example, has the highest
discriminative power for a special diagnostic problem?), and in
the choice of instruments (which instrument, or analytical
system, produces the least costs for special diagnostic
strategies?). Cost analysis is becoming more and more important
to decision-making in medical laboratories.
Although the need for cost analysis appears to be generMly
accepted, it is still undecided as to who should collect and
allocate costs and how this should be achieved. Comparison of
costs can only be useful if the processes of collection and
allocation are standardized and if definitions of terms used are
internationally accepted--the language applied must be under-
stood by all laboratory’ personnel.
The purpose ofthe symposium on cost analysis at Barcelona
was to provide a general summary of the present status of cost
analysis in the medical laboratory. Because ofa limit on time, the
reports presented could only introduce the field of costing. And
the symposium was intended to stimulate interest in costing
rather than to provide a detailed overview of the field.
The relation of the cost analysis symposium to automation
(the primary topic of the Barcelona Congress) was evident:
economical viewpoints are becoming more important, especially
in terms of expensive instrumentation and large, automated
multi-test systems which now influence the whole infrastructure
of a medical laboratory.
The papers read at the symposium follow.
Editor’s note: one symposium paper, received too late for
this issue, will be published in Journal ofAutomatic Chemistry,
Vol. 5, No. 3.
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The decision-making process surrounding the purchase ofnew
instruments in a medical laboratory involves several steps, and
many aspects have to be considered; this point was discussed
during the cost-analysis symposium organized by the IFCC’s
Expert Panel on Instrumentation in collaboration with the
IUPAC Commission on Automation and held at 1982’s
Barcelona meeting. The purpose of this paper is to discuss the
economic aspects of the process. Because large analytical
systems influence the whole organizational structure of the
laboratory, cost analysis and cost-benefit analysis must be
considered in respect of the total laboratory structure.
The primary task of the medical laboratory is to produce test
results--these usually lead to a number of effects:
Test
$ Expenditure
Result-- --,Efficiency
Effect(s)-- Effectiveness
The laboratory’s efficiency in fulfilling this task can be measured
by the quantity of results and by the costs incurred in obtaining
them (expenditure). The laboratory’s effectiveness is judged by
its ’utility’. (’Utility’ is a term commonly used in epidemiology
and in social economicsmsee references [1-8].)
Costs are usually considered in monetary units, whereas
utility can be monitored in monetary and in non-monetary
units. Before costs are discussed in detail a few aspects of utility
need to be considered.
Generally, an effective diagnostic strategy should lead to a
gain in utility. The expense must, in some way, serve the patient,
even if this is only a reduction in uncertainty [5]. The utility of
diagnostic and therapeutic steps can be a reduction of disease
course, a gain in life expectancy or prognostic hints. Utility can
be studied on a micro- or macroeconomic scale. In the first case,
utility is considered in a small unit (for example when buying a
new instrument); in the second, utility is looked at on a much
larger scale--its impact on a population for instance. If a
negative test result leads to an unjustified therapy being followed
or to an extension of a disease course, a loss of utility results.
’Net utility’ is the sum of all positive and negative utilities.
Cost-utility investigations have been divided into cost-
benefit and cost-effectiveness analyses [1-8] (see table 1).
In a cost-benefit analysis, expenses and utilities are con-
sidered in monetary units, these are finally summed so that theresult is an amount of money. In a cost-effectiveness analysis,
however, costs are collected in monetary units and utilities in
other units: these units may be years of life expectancy, days of
treatment, morbidity and mortality rates etc. The results are
expressed in, for instance, monetary units per number ofpersons
treated successfully.
The transformation of primarily non-monetary units into
monetary equivalents is difficult [2-9] and will not be discussed
here. Therefore, on one side all monetary gains and losses are
summed and on the other side are all the non-monetary positive
and negative utilities. The result of such an analysis is net costs
per net utilities.
Table 1. Cost-utility ana.yses.
Name of analysis
Cost-effectiveness
Cost-benefit analysis analysis
Result of analysis
Result of analysis
is an indicator for
Immediate costs per Total costs per
number of tests utility
Efficiency Effectiveness
The total expenses are often difficult to quantify, even ifonly
single tests have to be considered. A diagnostic strategy with
several simultaneously and/or sequentially performed tests
leads to an even more complicated cost analysis.
The total costs of a test (Ctot) consist of the immediate costs
(Ct) (caused by performing the test) and induced costs (Ci) (these
are related to the effects caused by the test). If a diagnostic-
therapeutic strategy is based on binary decisions, then the
expected induced costs (a priori induced costs) can be calculated
according to the formula:
AC=p.C
(p represents probability and C costs per event). The following
induced costs can be relevant to a cost-effectiveness analysis
[10]"
(1) Costs for further diagnostic procedures (ACsa).
(2) Costs for therapeutic actions taken because of positive
tests (including false positive results) (ACt).
(3) Costs incurred preventing morbidity (AC,,).
(4) Costs resulting from side-effects of the diagnostic
therapeutic strategy (AC,,).
(5) Costs incurred from diseases resulting from a pro-
longed life (AC1).
(6) Costs caused by omitting a necessary therapy as a
consequence of false negative results (ACs,,).
Summing these single costs leads to the induced costs Ci:
C ACa+ ACt-AC,,+ AC,,+ AC1 +AC,,.
So the cost-effectiveness equation can now be written as:
Ctot total net costs
Utot total net utilities
Whilst induced costs of a test are currently very difficult to
quantify, many laboratories have now started to record im-
mediate costs: this is known as ’cost accounting’.
Calculation ofa test’s costs requires collection ofall the costs
involved in performing a particular test. In some cases, however,
it is unnecessary to conduct such a comprehensive cost analysis.
For the purpose ofinvestment decisions it is sometimes sufficient
to consider only a part ofall costs. Such a problem-oriented cost
analysis will be discussed later.
Before collecting details ofcosts involved in a test, it needs to
be decided which costs are relevant. Usually, costs are divided
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into various kinds ofcosts.A criterion for this differentiation can
be the method ofdistribution: costs can be allocated directly or
indirectly [ 11 and 12].
Direct costs occur in relation to the test requested at the
principal cost centres, which usually correspond with the work
stations where the particular test is performed. Direct costs can
be attributed directly to the test (see table 2): they are either fixed,
semi-variable or variable. Fixed costs are time-related (figure 1),
but they are independent of the number of tests, as for example
the purchase cost ofan instrument. Variable costs depend on the
number oftests: costs ofreagents and disposables. Semi-variable
costs increase with the number oftests performed, usually this is
done at intervals--for example when the batch size has reached
a particular length. Staff costs can be either variable or
semivariable.
Indirect costs (see table 3) occur at overhead cost centres, for
example internal administration office or workshop. They have
to be distributed among the main cost centres.
In table 4 the most important test costs are listed. They
contain all the analytical and post-analytical, but not the pre-
analytical, costs. Pre-analytical costs concern preparation ofthe
patient, venipunctures and specimen transport.
A complete internal cost accounting, which covers all kinds
ofcosts and performs all the necessary allocation steps can only
be done, acceptably in terms of expense, if electronic data-
processing is available.
For assisting investment decisions, problem-oriented cost
analysis is often sufficient and requires only some ofthe costs. In
most investment decisions, a limited number ofalternatives have
Table 2. Direct costs.
1. Fixed costs
1.1 Costs of laboratory space
1.2 Depreciation of instruments
1.3 Interests
1.4 Maintenance and servicing
2. Semi-variable costs
2.1 Costs of personnel
2.2 Costs of quality control
3. Variable costs
3.1 Costs of reagents and purified water
3.2 Costs of disposables
3.3 Costs of power
3.4 Costs of repair
Fixed
Semi-variable
Batch size n
Figure 1. Fixed, variable and semi-variable costs.
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Table 3. Indirect costs.
1. Overheads inside the laboratory
1.1 Administration, management, postage, telephone charges,
insurance etc.
1.2 Data-processing
1.3 Cleaning
1.4 Cost distribution for staff rooms, floors etc.
1.5 Depreciation for basic instrumentation, furniture etc.
2. Overheads from outside the laboratory
2.1 Costs from other central institutions which perform services for the
laboratory
2.2 Share in the cost for central administration and operating of the
hospital
Table 4. Total costs of a bearer of costs (for example
determination of the glucose concentration, per year).
1. Variable costs
1.1 Reagents (including control materials)
1.2 Disposables
1.3 Costs of personnel
1.4 Power
1.5 Variable overhead costs of the cost centre
1.6 Overhead for central ,specimen distribution
1.7 Overhead for internal administration
1.8 Overhead for data-processing
2. Fixed costs
2.1 Depreciation
2.2 Interest charges
2.3 Service and maintenance
2.4 Fixed overhead costs of the cost centre
2.5 Quality control
3. Sum of variable and fixed costs
(1) Effective work time times cost for effective work per minute
(2) Allocated in per cent of the number of tests requested
Costs
ble costs
Fixed costs
lr
n n Batch size
Figure 2. The critical batch size (nc) as break-even-point.
’A’=(manual) procedure with lower mechanization than ’B’
(for example an automated procedure).
Table 5. Simplified calculation of the critical batch size
[14 and 15].
(CIB CfA)+ P" 1,11 (tBx tA1) qt_ p. 0,11 (tAa tn2)
(RtA-- Rtn)+ (Dta Dtn)+ P" 0,01 (ta2 tA1 tl + tB1
CI= Fixed costs
Rt-Reagent costs per test
Dr=Costs of disposables per test
t= Technician time for nl specimen (tl) and for nz specimen (t2)
A,B= Procedure A (manual or less mechanized)
and B (more mechanized or automated)
to becompared with each other. Only those direct costs in which
relevant differences are expected need to be considered. The
costs for the alternative investments are listed (see, for example,
table 4), and the sums are compared with each other: this is a
simple cost-benefit analysis. The expenses for an investment are
the costs in monetary units, the effect is in terms of, for example,
a reduction in personnel time. Since personnel time can be
transformed into monetary units, a cost-benefit analysis as
demonstrated of micro-economical area [ 1], is both useful and
fairly common.
Another procedure calculates the break-even point at which
two alternative solutions produce the same total costs (figure 2).
This point has also been called the critical batch size I-14 and 15].
It defines the average number of tests which have to be
performed in a daily batch in order to cost the same amount of
money for two alternatives. If fewer tests have to be performed
then solution A is cheaper; ifmore tests, as stated by the critical
batch size, have to be performed then solution B is the more
economical. It has been shown that only five data are required to
calculate the critical batch size (see table 5).
After this general introduction to the area oflaboratory cost
analysis, the following papers will cover more specific topics.
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